To identify factors that may contribute to the immunogenicity of MLKL-driven local necroptotic tumor cell death, we performed a broad cytokine and chemokine screening within the TME of either wild-type or MLKL−/− tumors in mice undergoing checkpoint inhibitor immunotherapy. Here, MLKL is linked to neoplasm.